The DSO Deal Behind the Headline Multiple: Private Equity, Debt, and the New Economics of Dental Practice Sales
For years, the dental practice sale was easy to picture. A younger dentist bought the practice, the seller collected a check, stayed for a transition, and eventually walked away. The modern DSO transaction can look very different. A dentist may receive cash, rollover equity, an earnout, a seller note, a new employment agreement, and a promise that the remaining equity will become more valuable in a future recapitalization. The headline number can be dazzling. The economic reality may be much harder to see.
That distinction matters because dentistry is now deeply connected to institutional capital. Private equity affiliation among dentists nearly doubled from 6.6 percent in 2015 to 12.8 percent in 2021, according to research published in Health Affairs. Larger groups and specialty practices have been especially attractive targets. Consolidation is no longer a side story in dentistry. It is changing who owns practices, how growth is financed, how dentists are compensated, and how financial pressure can travel from a corporate balance sheet all the way to staffing, scheduling, case presentation, and treatment mix.
The first mistake is judging a DSO offer by the EBITDA multiple alone. A practice offered eight times EBITDA has not necessarily received a better deal than one offered six times. The real question is what the dentist is actually receiving and what risks remain after closing. A hypothetical $10 million transaction might include $6 million in cash, $2 million in rollover equity, a $1 million earnout, and a $1 million seller note. Economically, that is not the same as receiving $10 million in cash. The dentist has sold a practice, but has also become an investor, creditor, employee, and sometimes minority shareholder in a much larger organization.
Current transaction advisers generally place many DSO add on acquisitions in the range of roughly five to eight times EBITDA, with larger platform businesses commanding substantially higher multiples. Those figures vary widely by size, specialty, growth, provider dependence, payer mix, and market conditions. The important point is not the exact multiple. It is that the price printed on the first page of the deal is only one dimension of value. The second is how EBITDA was calculated. The third is how the purchase price is paid. A high multiple combined with aggressive EBITDA adjustments, illiquid equity, contingent payments, weak minority protections, or heavy leverage above the dentist can ultimately be worth less than a lower and more certain offer.
Dental Care Alliance offers a useful case study because the facts are public. In 2026, DCA completed a major restructuring that eliminated more than $1.1 billion of funded debt, added $95 million of new capital, and extended remaining debt maturities to 2031. Its practices continued operating. Patients continued being treated. More than 400 affiliated practices and roughly 900 dentists were not simply erased because the parent company had a balance sheet problem. The operating business and the capital structure were two different things.
That distinction should be burned into the mind of any dentist taking rollover equity. Your practice can be busy, productive, and clinically healthy while the organization above it is financially stressed. Lenders are paid according to the capital structure, not according to how proud you are of yesterday’s production. New capital can dilute existing owners. Debt can be restructured. Equity can lose value even while the hygiene schedule remains full. DCA’s restructuring does not prove that dentists were deceived, that patients were harmed, or that every shareholder lost money. It proves something narrower and more useful. A large dental organization can require a massive financial reset while its practices continue functioning.
Affordable Care provides another warning about the financing environment. The company was acquired in a leveraged buyout valued at about $2.7 billion in 2021, when money was much cheaper. In 2026, reporting from The Wall Street Journal and Octus said Affordable Care had hired restructuring advisers while carrying more than $1 billion of private credit debt. Rising labor costs, workforce shortages, weaker consumer demand, and higher borrowing costs were all part of the pressure. Much of the debt associated with leveraged acquisitions can carry floating rates, so a deal that looked manageable when capital was inexpensive can become far more difficult when interest expense rises.
Dentists often hear that the Federal Reserve has stopped raising rates and assume the problem is fading. That is too simple. In August 2026, the federal funds target remained at 3.50 percent to 3.75 percent, and economists surveyed by Reuters largely expected rates to stay there through the end of the year. At the same time, Treasury yields had been rising. Treasury rates are the starting point for much of corporate borrowing. A DSO that needs to refinance can therefore face higher borrowing costs even if the Fed does nothing. Holding rates steady does not mean money has become cheap again.
MB2 Dental shows the other side of the story. It has grown rapidly, completed repeated recapitalizations, and provided documented liquidity opportunities to participating shareholders. In 2024, Warburg Pincus invested $525 million in a recapitalization valuing MB2 above $3.5 billion. Charlesbank reported that MB2 had added more than 450 partnerships since its 2021 investment and that revenue and EBITDA had grown by more than 30 percent annually during that period. MB2 has also used substantial institutional debt. In 2024 it closed a $2.344 billion unitranche credit facility led by KKR managed credit vehicles to help finance acquisitions and growth.
That matters because MB2 is sometimes held up as evidence that outside capital is not the problem, and that is largely correct. It is not a low leverage, dentist only enterprise. It combines dentist ownership with major private equity investors, institutional lenders, repeated recapitalizations, and large scale acquisition financing. The relevant question is not whether private equity is present. The relevant questions are whether the organization can support its debt, whether its doctors remain productive and engaged, whether the governance structure protects clinical autonomy, and whether dentist shareholders have a credible path from paper value to actual liquidity.
The same caution applies when criticizing other groups. Public evidence does not support treating every rapidly growing DSO as financially distressed. ICON Dental Partners says it has no outside private equity investors, is doctor controlled, and gives dentists voting control of its board. A 2026 Great Place to Work survey reported unusually high employee satisfaction, although that survey reflects corporate employees and cannot establish the experience or investment returns of every dentist partner. GPS Dental, backed by Main Post Partners, grew from 23 practices in 2021 to about 100 locations by late 2024. Rapid expansion can increase risk, but expansion alone is not evidence of failure. Without debt levels, cash flow, acquisition multiples, dentist retention, and realized partner returns, the rest is speculation.
The independent research suggests the same need for restraint. A 2026 Health Services Research study found that after private equity acquisition, dental practices increased listed charges by 3.3 percent, while negotiated insurer allowed amounts did not change significantly. Acquired practices also shifted toward more restorative, specialty, and surgical procedures and were more likely to become multispecialty. That finding deserves attention because ownership clearly can change the economic environment of a practice. It does not prove overtreatment. A richer procedure mix could reflect better specialty access, changed referral patterns, improved case capture, different patients, or stronger financial incentives. The study establishes the change, not the motive.
That distinction reaches the operatory. A dentist practicing inside any organization, private, DSO, or private equity backed, should be able to explain why a treatment recommendation exists clinically before explaining why it makes sense financially. The easiest way for financial pressure to damage trust is when case acceptance becomes the goal rather than the consequence of good diagnosis and communication. Patients can sense when a treatment conversation feels like a sales process. Strong organizations protect the separation between clinical necessity and financial performance, even while measuring both.
Research outside dentistry provides another signal. A 2025 Health Affairs study of ophthalmology practices found that clinician headcount grew after private equity acquisition, but physician turnover also increased substantially. The study does not prove the same effect occurs in dentistry, but the question is directly relevant to a practice sale. A growing organization can be adding providers while simultaneously losing many of the clinicians who were there before. For a selling dentist, one of the most revealing due diligence questions may therefore be simple. Of the dentists who were here three years ago, how many are still here?
At the same time, evidence does not support the claim that private equity automatically worsens patient outcomes. A 2026 JAMA Health Forum study of primary care found no significant increase in all cause or potentially preventable hospitalizations after private equity acquisition. Emergency department use changed little. That was primary care, not dentistry, and hospitalization is a blunt measure of quality, but the result is important. Ownership structure is not a substitute for outcome data. Private equity can create pressure, capital, technology, purchasing power, recruiting infrastructure, and operational discipline. Which of those forces dominates depends on the organization.
KKR provides perhaps the clearest example of how sophisticated investors now view dentistry. KKR is not simply buying dental practices. It owns a majority interest in Heartland Dental, which has grown from roughly 850 supported practices when KKR invested in 2018 to more than 1,900 locations and more than 3,000 supported dentists. KKR also holds an equity interest in Canada’s 123Dentist, has a major strategic minority position in Henry Schein, recapitalized DentalXChange, and led the $2.344 billion credit facility for MB2. These are different investments at different places in the dental economy.
Henry Schein is particularly revealing. KKR’s beneficial ownership reached about 16.4 percent by March 2026, and Henry Schein has allowed KKR to increase that position as high as 19.9 percent under its strategic agreement. KKR also has two board representatives. Henry Schein is far more than a supply distributor. Its businesses include dental merchandise, equipment, implants, biomaterials, specialty products, software, and other technology. In early 2026, Henry Schein’s traditional distribution business produced gross margins around 26 percent, while specialty products were above 55 percent and technology approached 69 percent. The direction of travel is obvious. Distribution provides reach. Proprietary products and technology provide richer margins.
DentalXChange adds another layer. The company connects practices, practice management systems, and payers through claims, eligibility, attachments, and other revenue cycle transactions. It facilitates billions of transactions annually and serves nearly 200,000 dental providers. For an investor, this resembles infrastructure. It can benefit whether the dentist is independent, works for a DSO, changes practice software, or sells the practice entirely. Dentistry still has to turn treatment into a claim and a claim into cash.
Manufacturing may be the next logical extension. KKR was reported in 2025 to be discussing an acquisition of Leixir Dental Laboratory Group for roughly $200 million to $250 million. No completed acquisition has been publicly confirmed, but the interest itself is significant. Leixir already serves Heartland Dental under a partnership extended through 2029. KKR has since launched Allyntra, a precision medical manufacturing platform designed to acquire and integrate engineered healthcare businesses, and in August 2026 agreed to acquire medical device manufacturer Integer Holdings in a transaction valued at about $5.7 billion. Dental manufacturing clearly fits within KKR’s broader healthcare playbook, particularly in implants, biomaterials, digital prosthetics, laboratories, CAD CAM, and precision devices.
Finance may be even more natural. KKR manages nearly $800 billion in assets, including an enormous credit platform and insurance capital looking for contractual cash flows. Its asset based finance business has already purchased large pools of Buy Now, Pay Later loans from PayPal while allowing PayPal to keep the customer relationship and continue originating loans. The model could translate easily to dentistry. A financing company could approve a patient for a $20,000 implant case, pay the dentist, and sell or finance the resulting receivable through institutional capital. KKR would not need to own the dental financing brand. It could own the dental loans.
For practicing dentists, this may sound far removed from the operatory, but it is not. Capital influences which practices are bought, how much debt organizations carry, what growth targets are expected, how aggressively specialty services are developed, how much is invested in technology, and how much pressure exists to improve margins. Those pressures can eventually affect staffing, appointment lengths, compensation plans, treatment presentation, and the financial options offered to patients. Good leadership can use scale to remove administrative friction and expand access. Poorly designed incentives can turn the same scale into pressure that clinicians and patients feel.
The practical lesson is not to reject DSOs, private equity, or debt. It is to understand what you are actually buying and selling. Before accepting rollover equity, know how much debt sits above it, when that debt matures, whether rates are fixed or floating, what rights new investors have, how dilution works, what happens in a restructuring, and whether previous dentists have actually converted their equity into cash. Before trusting a buyer’s references, speak with doctors the buyer did not select, including those who left. Look at doctor retention, not just office count. Ask how compensation changed after closing, how clinical autonomy is protected in writing, and what happens if the practice misses its forecast.
Most of all, separate the practice from the capital structure. A beautiful office, loyal team, strong hygiene department, and excellent case acceptance do not guarantee that equity in the parent company is safe. Conversely, a leveraged organization is not automatically a bad clinical environment. Dentistry is now operating inside a much more sophisticated financial system, and dentists who understand only the clinical side of the transaction are negotiating with people who understand both.
The next time a DSO puts an extraordinary number on your practice, will you ask what the number is, or what it is really worth?
Join the Conversation!